Skip to main content
Literatur
1.
Zurück zum Zitat Irvine K, Laws KR, Gale TM, Kondel TK (2012) Greater cognitive deterioration in women than men with Alzheimer’s disease: a meta analysis. J Clin Exp Neuropsychol 34(9):989–998CrossRefPubMed Irvine K, Laws KR, Gale TM, Kondel TK (2012) Greater cognitive deterioration in women than men with Alzheimer’s disease: a meta analysis. J Clin Exp Neuropsychol 34(9):989–998CrossRefPubMed
2.
Zurück zum Zitat Altmann A, Tian L, Henderson VW, Greicius MD (2014) Alzheimer’s disease neuroimaging initiative I. Sex modifies the APOE-related risk of developing alzheimer disease. Ann Neurol 75(4):563–573CrossRefPubMedPubMedCentral Altmann A, Tian L, Henderson VW, Greicius MD (2014) Alzheimer’s disease neuroimaging initiative I. Sex modifies the APOE-related risk of developing alzheimer disease. Ann Neurol 75(4):563–573CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Epperson CN, Sammel MD, Freeman EW (2013) Menopause effects on verbal memory: findings from a longitudinal community cohort. J Clin Endocrinol Metab 98(9):3829–3838CrossRefPubMedPubMedCentral Epperson CN, Sammel MD, Freeman EW (2013) Menopause effects on verbal memory: findings from a longitudinal community cohort. J Clin Endocrinol Metab 98(9):3829–3838CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Maki PM, Drogos LL, Rubin LH, Banuvar S, Shulman LP, Geller SE (2008) Objective hot flashes are negatively related to verbal memory performance in midlife women. Menopause 15(5):848–856CrossRefPubMedPubMedCentral Maki PM, Drogos LL, Rubin LH, Banuvar S, Shulman LP, Geller SE (2008) Objective hot flashes are negatively related to verbal memory performance in midlife women. Menopause 15(5):848–856CrossRefPubMedPubMedCentral
5.
6.
Zurück zum Zitat Henderson VW (2014) Alzheimer’s disease: review of hormone therapy trials and implications for treatment and prevention after menopause. J Steroid Biochem Mol Biol 142:99–106CrossRefPubMed Henderson VW (2014) Alzheimer’s disease: review of hormone therapy trials and implications for treatment and prevention after menopause. J Steroid Biochem Mol Biol 142:99–106CrossRefPubMed
7.
Zurück zum Zitat Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS et al (2015) Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-cognitive and affective study. PLOS Med 12(6):e1001833 (discussion e)CrossRefPubMedPubMedCentral Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS et al (2015) Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-cognitive and affective study. PLOS Med 12(6):e1001833 (discussion e)CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc ES et al (2013) Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med 173(15):1429–1436CrossRefPubMed Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc ES et al (2013) Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med 173(15):1429–1436CrossRefPubMed
9.
Zurück zum Zitat Guennoun R, Labombarda F, Gonzalez Deniselle MC, Liere P, De Nicola AF, Schumacher M (2015) Progesterone and allopregnanolone in the central nervous system: response to injury and implication for neuroprotection. J Steroid Biochem Mol Biol 146:48–61CrossRefPubMed Guennoun R, Labombarda F, Gonzalez Deniselle MC, Liere P, De Nicola AF, Schumacher M (2015) Progesterone and allopregnanolone in the central nervous system: response to injury and implication for neuroprotection. J Steroid Biochem Mol Biol 146:48–61CrossRefPubMed
10.
Zurück zum Zitat Schumacher M, Denier C, Oudinet JP, Adams D, Guennoun R (2016) Progesterone neuroprotection: the background of clinical trial failure. J Steroid Biochem Mol Biol 160:53–66CrossRefPubMed Schumacher M, Denier C, Oudinet JP, Adams D, Guennoun R (2016) Progesterone neuroprotection: the background of clinical trial failure. J Steroid Biochem Mol Biol 160:53–66CrossRefPubMed
11.
Zurück zum Zitat Hitchcock CL, Prior JC (2012) Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women. Menopause 19(8):886–893CrossRefPubMed Hitchcock CL, Prior JC (2012) Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women. Menopause 19(8):886–893CrossRefPubMed
12.
Zurück zum Zitat Prior JC, Elliott TG, Norman E, Stajic V, Hitchcock CL (2014) Progesterone therapy, endothelial function and cardiovascular risk factors: a 3-month randomized, placebo-controlled trial in healthy early postmenopausal women. PLOS ONE 9(1):e84698CrossRefPubMedPubMedCentral Prior JC, Elliott TG, Norman E, Stajic V, Hitchcock CL (2014) Progesterone therapy, endothelial function and cardiovascular risk factors: a 3-month randomized, placebo-controlled trial in healthy early postmenopausal women. PLOS ONE 9(1):e84698CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Murkes D, Lalitkumar PG, Leifland K, Lundstrom E, Soderqvist G (2012) Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo. Gynecol Endocrinol 28(Suppl 2):12–15CrossRefPubMed Murkes D, Lalitkumar PG, Leifland K, Lundstrom E, Soderqvist G (2012) Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo. Gynecol Endocrinol 28(Suppl 2):12–15CrossRefPubMed
14.
15.
Zurück zum Zitat Cervelló I, Gil-Sanchis C, Mas A et al (2010) Human endometrial side population cells exhibit genotypic, phenotypic and functional features of somatic stem cells. PLOS ONE 5:e10964CrossRefPubMedPubMedCentral Cervelló I, Gil-Sanchis C, Mas A et al (2010) Human endometrial side population cells exhibit genotypic, phenotypic and functional features of somatic stem cells. PLOS ONE 5:e10964CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Santamaria X, Cabanillas S, Cervelló I et al (2016) Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman’s syndrome and endometrial atrophy: a pilot cohort study. Hum Reprod 31:1087–1096CrossRefPubMed Santamaria X, Cabanillas S, Cervelló I et al (2016) Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman’s syndrome and endometrial atrophy: a pilot cohort study. Hum Reprod 31:1087–1096CrossRefPubMed
17.
Zurück zum Zitat Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P et al (2015) Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab 100(12):4588–4594CrossRefPubMed Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P et al (2015) Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab 100(12):4588–4594CrossRefPubMed
18.
Zurück zum Zitat Mosher W, Jones J, Abma J (2015) Nonuse of contraception among women at risk of unintended pregnancy in the United States. Contraception 92(2):170–176CrossRefPubMed Mosher W, Jones J, Abma J (2015) Nonuse of contraception among women at risk of unintended pregnancy in the United States. Contraception 92(2):170–176CrossRefPubMed
19.
Zurück zum Zitat Al-Hassan N (2011) Guidance on contraception for women aged over 40 years. J Fam Plann Reprod Health Care 37(2):124–125 (discussion 5)CrossRefPubMed Al-Hassan N (2011) Guidance on contraception for women aged over 40 years. J Fam Plann Reprod Health Care 37(2):124–125 (discussion 5)CrossRefPubMed
Metadaten
Titel
Neues und praktisch Relevantes aus der gynäkologischen Endokrinologie
verfasst von
Prof. Dr. M. von Wolff
Prof. Dr. P. Stute
Publikationsdatum
17.03.2017
Verlag
Springer Medizin
Erschienen in
Gynäkologische Endokrinologie / Ausgabe 2/2017
Print ISSN: 1610-2894
Elektronische ISSN: 1610-2908
DOI
https://doi.org/10.1007/s10304-017-0125-3

Weitere Artikel der Ausgabe 2/2017

Gynäkologische Endokrinologie 2/2017 Zur Ausgabe

Mitteilungen der DMG

Mitteilungen der DMG

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.